Aytu Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aytu BioPharma licenses EXXUA for MDD and raises $16.6M to support commercialization.
NASDAQ
Aytu BioPharma reports a net loss of $15.8 million for fiscal year 2024, while strategically shifting focus to its Rx segment and completing the divestiture of its Consumer Health segment.